Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Boehringer Ingelheim
Dow
Harvard Business School
McKinsey

Last Updated: May 25, 2022

TRIUMEQ Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Triumeq, and when can generic versions of Triumeq launch?

Triumeq is a drug marketed by Viiv Hlthcare and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-eight patent family members in thirty-three countries.

The generic ingredient in TRIUMEQ is abacavir sulfate; dolutegravir sodium; lamivudine. There are twelve drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the abacavir sulfate; dolutegravir sodium; lamivudine profile page.

DrugPatentWatch® Generic Entry Outlook for Triumeq

Triumeq was eligible for patent challenges on August 12, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 8, 2029. This may change due to patent challenges or generic licensing.

There have been twenty-one patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Drug patent expirations by year for TRIUMEQ
Drug Prices for TRIUMEQ

See drug prices for TRIUMEQ

DrugPatentWatch® Estimated Generic Entry Opportunity Date for TRIUMEQ
Generic Entry Date for TRIUMEQ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TRIUMEQ

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
King's College LondonPhase 3
Macquarie University, AustraliaPhase 3
Stichting TRICALS FoundationPhase 3

See all TRIUMEQ clinical trials

Paragraph IV (Patent) Challenges for TRIUMEQ
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
TRIUMEQ Tablets abacavir sulfate; dolutegravir sodium; lamivudine 600 mg/50 mg/ 300 mg 205551 5 2017-08-14

US Patents and Regulatory Information for TRIUMEQ

TRIUMEQ is protected by two US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of TRIUMEQ is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting TRIUMEQ

Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare TRIUMEQ abacavir sulfate; dolutegravir sodium; lamivudine TABLET;ORAL 205551-001 Aug 22, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Viiv Hlthcare TRIUMEQ abacavir sulfate; dolutegravir sodium; lamivudine TABLET;ORAL 205551-001 Aug 22, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Viiv Hlthcare TRIUMEQ PD abacavir sulfate; dolutegravir sodium; lamivudine TABLET, FOR SUSPENSION;ORAL 215413-001 Mar 30, 2022 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TRIUMEQ

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare TRIUMEQ abacavir sulfate; dolutegravir sodium; lamivudine TABLET;ORAL 205551-001 Aug 22, 2014 See Plans and Pricing See Plans and Pricing
Viiv Hlthcare TRIUMEQ abacavir sulfate; dolutegravir sodium; lamivudine TABLET;ORAL 205551-001 Aug 22, 2014 See Plans and Pricing See Plans and Pricing
Viiv Hlthcare TRIUMEQ abacavir sulfate; dolutegravir sodium; lamivudine TABLET;ORAL 205551-001 Aug 22, 2014 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for TRIUMEQ

When does loss-of-exclusivity occur for TRIUMEQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 09325128
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 0923217
Estimated Expiration: See Plans and Pricing

Canada

Patent: 44019
Estimated Expiration: See Plans and Pricing

Patent: 55957
Estimated Expiration: See Plans and Pricing

China

Patent: 2245182
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 76080
Estimated Expiration: See Plans and Pricing

Patent: 10603
Estimated Expiration: See Plans and Pricing

Hong Kong

Patent: 43626
Estimated Expiration: See Plans and Pricing

Japan

Patent: 86478
Estimated Expiration: See Plans and Pricing

Patent: 48595
Estimated Expiration: See Plans and Pricing

Patent: 30891
Estimated Expiration: See Plans and Pricing

Patent: 12131791
Estimated Expiration: See Plans and Pricing

Patent: 12511573
Estimated Expiration: See Plans and Pricing

Patent: 16041727
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 1942
Estimated Expiration: See Plans and Pricing

Patent: 11006241
Estimated Expiration: See Plans and Pricing

Russian Federation

Patent: 27451
Estimated Expiration: See Plans and Pricing

Patent: 38923
Estimated Expiration: See Plans and Pricing

Patent: 11121785
Estimated Expiration: See Plans and Pricing

Patent: 13153004
Estimated Expiration: See Plans and Pricing

Singapore

Patent: 1308
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1733625
Estimated Expiration: See Plans and Pricing

Patent: 1847887
Estimated Expiration: See Plans and Pricing

Patent: 110094336
Estimated Expiration: See Plans and Pricing

Patent: 170038116
Estimated Expiration: See Plans and Pricing

Spain

Patent: 41765
Estimated Expiration: See Plans and Pricing

Taiwan

Patent: 83947
Estimated Expiration: See Plans and Pricing

Patent: 1030010
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRIUMEQ around the world.

Country Patent Number Title Estimated Expiration
Czech Republic 284513 (-)cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan 5-yl)-(1H)-pyrimidin-2-on v krystalické formě ((-)CIS-4-AMINO-1-(2-HYDROXYMETHYL-1,3-OXATHIOLAN-5-YL)- (1H)PYRIMIDIN-2-ONE IN CRYSTALLINE FORM, PROCESS OF ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF) See Plans and Pricing
Norway 974510 See Plans and Pricing
Australia 1881092 See Plans and Pricing
Australia 2009325128 Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates See Plans and Pricing
European Patent Office 0979082 See Plans and Pricing
Denmark 3045206 See Plans and Pricing
China 1185110 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for TRIUMEQ

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0817637 SPC016/2005 Ireland See Plans and Pricing SPC016/2005: 20060407, EXPIRES: 20191216
0817637 91171 Luxembourg See Plans and Pricing 91171, EXPIRES: 20191217
1874117 122014000066 Germany See Plans and Pricing PRODUCT NAME: DOLUTEGRAVIR ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ ODER SOLVAT DAVON, EINSCHLIESSLICH DOLUTEGRAVIRNATRIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140116
2465580 CA 2021 00010 Denmark See Plans and Pricing PRODUCT NAME: CABOTEGRAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF; REG. NO/DATE: EU/1/20/1481 20201221
1874117 300676 Netherlands See Plans and Pricing PRODUCT NAME: DOLUTEGRAVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN, MET INBEGRIP VAN DOLUTEGRAVIR NATRIUM; REGISTRATION NO/DATE: EU/1/13/892 20140121
0817637 288 Finland See Plans and Pricing
1874117 PA2014021 Lithuania See Plans and Pricing PRODUCT NAME: DOLUTEGRAVIRUM NATRICUM; REGISTRATION NO/DATE: EU/1/13/892/001, 2014 01 16 EU/1/13/892/002 20140116
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Moodys
Merck
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.